Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYumeng ZhangSGSameh GaballaHSHayder Saeed

Discussion

Loading...

Member takes

Overview

Real-world analysis shows elevated cytokine-release syndrome and neurotoxicity in non-Hodgkin lymphoma patients receiving bispecific antibodies.

Key Points

  • CRS occurred in 35.8% of patients with grade 3–4 cases at 6.2%, indicating a notable toxicity profile.
  • Elevated baseline ferritin associated with increased cytokine-release syndrome severity in non-Hodgkin lymphoma patients.
  • Assessment of CNS involvement revealed higher odds of immune-effector-cell–associated neurotoxicity syndrome risk with an OR of 5.16.
  • Frequent comorbidities and high rates of hypogammaglobulinemia emphasize the need for diligent supportive care and management.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc3ahttps://doi.org/10.1182/blood-2025-8017
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.2025
  2. 2Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium2025
  3. 3Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper2025
  4. 4Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations2025
  5. 5Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma2025